Balyasny Asset Management
INO icon

Balyasny Asset Management’s Inovio Pharmaceuticals INO Stock Holding History

Balyasny Asset Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-22,246
Closed -$309K – 2825
2024
Q1 		$309K Buy
+22,246
New +$192K ﹤0.01% 2249
2023
Q4 		– Sell
-1,524
Closed -$7.11K – 2682
2023
Q3 		$7.11K Sell
1,524
-5,662
-79% -$31.3K ﹤0.01% 2186
2023
Q2 		$38.5K Buy
+7,186
New +$57.9K ﹤0.01% 2139
2023
Q1 		– Sell
-4,055
Closed -$75.9K – 2892
2022
Q4 		$75.9K Sell
4,055
-1,389
-26% -$31.5K ﹤0.01% 2284
2022
Q3 		$113K Buy
5,444
+737
+16% +$18.9K ﹤0.01% 2395
2022
Q2 		$98K Buy
+4,707
New +$133K ﹤0.01% 2283
2020
Q2 		– Sell
-27,791
Closed -$2.48M – 1303
2020
Q1 		$2.48M Buy
+27,791
New +$1.71M 0.03% 575
2016
Q1 		– Sell
-2,992
Closed -$241K – 1385
2015
Q4 		$241K Buy
+2,992
New +$238K ﹤0.01% 1042

Other funds holding INO

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Balyasny Asset Management's INO Position: Q2 2024 in Review

Balyasny Asset Management sold out of Inovio Pharmaceuticals (INO) in Q2 2024, closing a stake of 22,246 shares — an estimated $309K sold.

Balyasny Asset Management first reported a position in INO in Q4 2015 and held it in 8 quarters. The position peaked at $2.48M in Q1 2020. 96 funds tracked by Wall St. Rank hold INO as of Q2 2024.

  • Balyasny Asset Management reported no remaining Inovio Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 22,246 Inovio Pharmaceuticals shares in Q2 2024, an estimated $309K.
  • Balyasny Asset Management first reported a position in Inovio Pharmaceuticals in Q4 2015 and held it in 8 quarters.
  • Balyasny Asset Management's Inovio Pharmaceuticals position peaked at $2.48M in Q1 2020.
  • 96 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2024.

Based on Balyasny Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.